2006•Zhongguo xin yao zazhiRequires access

Efficacy and safety of reboxetine versus fluoxetine for the elders with depression

Yu Li

Abstract

Objective:To evaluate the efficacy and safety of reboxetine versus fluoxetine in the elder patients with depression. Methods:60 patients who met the diagnostic criteria of depression of CC-MD-3 were randomly treated with reboxetine (4 -8 mg) or fluoxetine (20 - 40 mg) daily for 4 weeks. The efficacy and safety of therapy was assessed based on HAMD, CGI and TESS before and after treatment. Results:The effective rate of reboxetine versus fluoxetine was 80.00% versus 70.00% (P 0. 05 ). The side effects incidence of reboxetine showed no statistical difference from fluoxetine. Conclusion: Reboxetine offers effective and safe therapeutic option for geriatrics with depression.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Reboxetine, Fluoxetine, Hamd, Depression (economics), Medicine, Significant difference, Pharmacology, Psychology